Last reviewed · How we verify
Matching placebo to Ramipril
This is a matching placebo formulation designed to mimic Ramipril, an ACE inhibitor that lowers blood pressure by blocking angiotensin-converting enzyme.
This is a matching placebo formulation designed to mimic Ramipril, an ACE inhibitor that lowers blood pressure by blocking angiotensin-converting enzyme. Used for Clinical trial control for Ramipril studies in hypertension, Clinical trial control for Ramipril studies in heart failure or post-myocardial infarction.
At a glance
| Generic name | Matching placebo to Ramipril |
|---|---|
| Sponsor | Novartis |
| Drug class | Placebo (matching formulation for ACE inhibitor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this product contains no active pharmaceutical ingredient and is used as a control in clinical trials to compare against active Ramipril treatment. Ramipril itself works by inhibiting ACE, which prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and cardiac workload.
Approved indications
- Clinical trial control for Ramipril studies in hypertension
- Clinical trial control for Ramipril studies in heart failure or post-myocardial infarction
Common side effects
Key clinical trials
- Role of Vitamin K2 in Chronic Kidney Disease (PHASE4)
- Role of Coenzyme Q10 in Chronic Kidney Disease (PHASE4)
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PHASE3)
- Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study (PHASE2)
- Ramipril for the Treatment of Oligospermia (NA)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Aliskiren Study of Safety and Efficacy in Senior Hypertensives (PHASE4)
- Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo to Ramipril CI brief — competitive landscape report
- Matching placebo to Ramipril updates RSS · CI watch RSS
- Novartis portfolio CI